Skin Barrier Recovery by Protease-Activated Receptor-2 Antagonist Lobaric Acid

Overview

Journal Biomol Ther (Seoul)

Specialty Pharmacology

Date 2016 May 13

PMID 27169822

Citations 5

Authors

Yeon Ah Joo

Hyunjin Chung

Sohyun Yoon

Jong Il Park

Ji Eun Lee

Cheol Hwan Myung

Jae Sung Hwang

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) results from gene and environment interactions that lead to a range of immunological abnormalities and breakdown of the skin barrier. Protease-activated receptor 2 (PAR2) belongs to a family of G-protein coupled receptors and is expressed in suprabasal layers of the epidermis. PAR2 is activated by both trypsin and a specific agonist peptide, SLIGKV-NH₂ and is involved in both epidermal permeability barrier homeostasis and epithelial inflammation. In this study, we investigated the effect of lobaric acid on inflammation, keratinocyte differentiation, and recovery of the skin barrier in hairless mice. Lobaric acid blocked trypsin-induced and SLIGKV-NH2-induced PAR2 activation resulting in decreased mobilization of intracellular Ca²⁺ in HaCaT keratinocytes. Lobaric acid reduced expression of interleukin-8 induced by SLIGKV-NH₂ and thymus and activation regulated chemokine (TARC) induced by tumor necrosis factor-a (TNF-α) and IFN-γ in HaCaT keratinocytes. Lobaric acid also blocked SLIGKV-NH₂-induced activation of ERK, which is a downstream signal of PAR2 in normal human keratinocytes (NHEKs). Treatment with SLIGKV-NH₂ downregulated expression of involucrin, a differentiation marker protein in HaCaT keratinocytes, and upregulated expression of involucrin, transglutamase1 and filaggrin in NHEKs. However, lobaric acid antagonized the effect of SLIGKV-NH₂ in HaCaT keratinocytes and NHEKs. Topical application of lobaric acid accelerated barrier recovery kinetics in a SKH-1 hairless mouse model. These results suggested that lobaric acid is a PAR2 antagonist and could be a possible therapeutic agent for atopic dermatitis.

Citing Articles

Discovery and excavation of lichen bioactive natural products.

Ren M, Jiang S, Wang Y, Pan X, Pan F, Wei X Front Microbiol. 2023; 14:1177123.

PMID: 37138611 PMC: 10149937. DOI: 10.3389/fmicb.2023.1177123.

Manipulation of tissue factor-mediated basal PAR-2 signalling on macrophages determines sensitivity for IFNγ responsiveness and significantly modifies the phenotype of murine DTH.

Wilkinson H, Leonard H, Robson M, Smith R, Tam E, McVey J Front Immunol. 2022; 13:999871.

PMID: 36172348 PMC: 9510775. DOI: 10.3389/fimmu.2022.999871.

3-Bromo-4,5-dihydroxybenzaldehyde Isolated from Suppresses TNF-α/IFN-γ-Stimulated Inflammation and Deterioration of Skin Barrier in HaCaT Keratinocytes.

Jayasinghe A, Han E, Kirindage K, Fernando I, Kim E, Kim J Mar Drugs. 2022; 20(9).

PMID: 36135752 PMC: 9504623. DOI: 10.3390/md20090563.

Topical Application of Galgeunhwanggeumhwangryeon-Tang Recovers Skin-Lipid Barrier and Ameliorates Inflammation via Filaggrin-Thymic Stromal Lymphopoietin-Interleukin 4 Pathway.

Ahn S, Shin S, Do Y, Jo Y, Ryu D, Ha K Medicina (Kaunas). 2021; 57(12).

PMID: 34946332 PMC: 8708970. DOI: 10.3390/medicina57121387.

Bioinformatic Analysis Identifies Potential Key Genes in the Pathogenesis of Melanoma.

Han Y, Li X, Yan J, Ma C, Wang X, Pan H Front Oncol. 2020; 10:581985.

PMID: 33178610 PMC: 7596746. DOI: 10.3389/fonc.2020.581985.

References

Elias P . Stratum corneum defensive functions: an integrated view. J Invest Dermatol. 2005; 125(2):183-200. DOI: 10.1111/j.0022-202X.2005.23668.x. View

Morita E, Takahashi H, Niihara H, Dekio I, Sumikawa Y, Murakami Y . Stratum corneum TARC level is a new indicator of lesional skin inflammation in atopic dermatitis. Allergy. 2010; 65(9):1166-72. DOI: 10.1111/j.1398-9995.2010.02361.x. View

Leung D, Boguniewicz M, Howell M, Nomura I, Hamid Q . New insights into atopic dermatitis. J Clin Invest. 2004; 113(5):651-7. PMC: 351324. DOI: 10.1172/JCI21060. View

Morita H, Tsuchiya T, Kishibe K, Noya S, Shiro M, Hirasawa Y . Antimitotic activity of lobaric acid and a new benzofuran, sakisacaulon A from Stereocaulon sasakii. Bioorg Med Chem Lett. 2009; 19(13):3679-81. DOI: 10.1016/j.bmcl.2009.03.170. View

Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek S, Smith A . Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol. 2002; 88(1):77-84. DOI: 10.1254/jjp.88.77. View

Elias P, Choi E . Interactions among stratum corneum defensive functions. Exp Dermatol. 2005; 14(10):719-26. DOI: 10.1111/j.1600-0625.2005.00363.x. View

Oldham W, Hamm H . Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2007; 9(1):60-71. DOI: 10.1038/nrm2299. View

Bohm S, Kong W, Bromme D, Smeekens S, Anderson D, Connolly A . Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996; 314 ( Pt 3):1009-16. PMC: 1217107. DOI: 10.1042/bj3141009. View

Frateschi S, Camerer E, Crisante G, Rieser S, Membrez M, Charles R . PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat Commun. 2011; 2:161. PMC: 3105307. DOI: 10.1038/ncomms1162. View

10.

Madison K . Barrier function of the skin: "la raison d'être" of the epidermis. J Invest Dermatol. 2003; 121(2):231-41. DOI: 10.1046/j.1523-1747.2003.12359.x. View

11.

Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C . Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009; 206(5):1135-47. PMC: 2715042. DOI: 10.1084/jem.20082242. View

12.

Derian C, Eckardt A, Andrade-Gordon P . Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. Cell Growth Differ. 1997; 8(7):743-9. View

13.

Hou L, Kapas S, Cruchley A, Macey M, Harriott P, Chinni C . Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology. 1998; 94(3):356-62. PMC: 1364253. DOI: 10.1046/j.1365-2567.1998.00528.x. View

14.

Guo D, Zhou H, Wu Y, Zhou F, Xu G, Wen H . Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620. Tumour Biol. 2011; 32(5):921-30. DOI: 10.1007/s13277-011-0194-1. View

15.

Jeong S, Kim H, Youm J, Ahn S, Choi E, Sohn M . Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol. 2008; 128(8):1930-9. DOI: 10.1038/jid.2008.13. View

16.

Elias P, Hatano Y, Williams M . Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008; 121(6):1337-43. PMC: 2706021. DOI: 10.1016/j.jaci.2008.01.022. View

17.

Gissurarson S, Sigurdsson S, Wagner H, Ingolfsdottir K . Effect of lobaric acid on cysteinyl-leukotriene formation and contractile activity of guinea pig taenia coli. J Pharmacol Exp Ther. 1997; 280(2):770-3. View

18.

Lee S, Jeong S, Lee S . Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J. 2010; 51(6):808-22. PMC: 2995962. DOI: 10.3349/ymj.2010.51.6.808. View

19.

Eckert R, Crish J, Robinson N . The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev. 1997; 77(2):397-424. DOI: 10.1152/physrev.1997.77.2.397. View

20.

Kim H, Goo J, Joo Y, Lee H, Lee S, Oh C . Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist. Biomol Ther (Seoul). 2013; 20(5):463-9. PMC: 3762283. DOI: 10.4062/biomolther.2012.20.5.463. View